Polycystic ovary syndrome (PCOS) affects approximately 10% of women of reproductive age and is the leading cause of anovulatory infertility. Weight management is a central challenge for women with PCOS, who often find traditional diet and exercise approaches less effective due to the metabolic disturbances inherent to the condition. GLP-1 receptor agonist medications are emerging as a promising tool for this population.
Why Weight Loss Is Especially Important in PCOS
PCOS is characterized by insulin resistance, elevated androgen levels, and often excess weight. These factors are interconnected: excess weight worsens insulin resistance, which increases androgen production, which promotes further weight gain. This cycle makes weight loss both more difficult and more impactful for women with PCOS.
Studies consistently show that even modest weight loss of 5-10% can significantly improve PCOS symptoms, including restoring menstrual regularity, improving ovulation rates, reducing androgen levels, and improving insulin sensitivity. For women struggling to conceive, weight loss can be a critical factor in achieving pregnancy.
GLP-1 Medications and Insulin Resistance
GLP-1 receptor agonists have particular relevance for PCOS because they address multiple aspects of the condition. Beyond promoting weight loss, GLP-1 medications improve insulin sensitivity, reduce fasting glucose levels, and lower A1C. For women with PCOS who have concurrent insulin resistance or pre-diabetes, these metabolic benefits compound the advantages of weight loss alone.
Liraglutide (Saxenda) was the first GLP-1 medication studied specifically in women with PCOS. Several small clinical trials demonstrated significant improvements in weight, insulin resistance markers, and menstrual regularity. More recently, semaglutide has shown even more promising results in preliminary studies, though large-scale randomized controlled trials specifically in PCOS populations are still ongoing.
Current Evidence
A 2025 systematic review and meta-analysis of GLP-1 receptor agonists in PCOS found that GLP-1 treatment was associated with an average weight loss of 5-8 kg, significant reductions in fasting insulin and HOMA-IR (a measure of insulin resistance), improvements in menstrual frequency, and reductions in free testosterone levels.
However, most of these studies are small and of short duration. The evidence base, while encouraging, is not yet at the level of the large-scale trials that supported GLP-1 approval for general obesity treatment.
Fertility Considerations
For women with PCOS who are trying to conceive, the relationship between GLP-1 medications and fertility requires careful consideration. Weight loss achieved through GLP-1 treatment can improve ovulation and fertility. However, GLP-1 medications themselves should be discontinued before attempting pregnancy, as their safety during pregnancy has not been established.
The recommended washout period before attempting conception varies by medication but is generally at least two months for semaglutide and one month for liraglutide. Discuss the timing of medication discontinuation and pregnancy attempts with both your prescribing physician and your reproductive endocrinologist.
Getting Insurance Coverage
Insurance coverage for GLP-1 medications when prescribed for PCOS-related weight management can be complex. Some insurers may cover these medications when prescribed for concurrent conditions like type 2 diabetes or pre-diabetes, which are common in PCOS. Documenting the full spectrum of PCOS-related metabolic disturbances in your medical records can strengthen coverage requests.
For detailed information on navigating insurance coverage for GLP-1 medications, see our complete guide to GLP-1 insurance coverage. For provider comparisons, a comprehensive comparison of 29+ providers is available at GLP-1 Watchdog.
Combined Treatment Approaches
Many endocrinologists treating PCOS now combine GLP-1 medications with other interventions for optimal results. Metformin, which has long been used in PCOS management, may complement GLP-1 therapy by providing additional insulin-sensitizing effects. Anti-androgen medications like spironolactone can address symptoms like acne and hirsutism while GLP-1 medications target the metabolic component.
Our Recommendation
For women with PCOS who have struggled with weight management despite lifestyle modifications, GLP-1 medications represent a genuinely promising option. The dual benefits of weight loss and insulin resistance improvement are particularly relevant to this population. However, treatment should be supervised by a provider who understands both PCOS and GLP-1 medications, and fertility planning must be carefully coordinated with medication use.